Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

FDA approves Sun Pharma’s IL-23 inhibitor for psoriatic arthritis. Credit: Stock.Adobe.com/Vitalii Vodolazskyi

October 30th, 2026

FDA Approves Ilumya for Adults With Active Psoriatic Arthritis

Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.

October 30th, 2026

Three Levels of Digital Clone Use Cases: Q&A with Hamish Brocklebank

Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.

October 30th, 2026

Post-Exposure Prophylaxis Is the Missing Piece: Q&A with Florin Draica

Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.

October 30th, 2026

Closing the Pediatric Evidence Gap

Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.

BioMarin pays $70 million upfront for a long-acting Fabry therapy, while Ferring agrees to acquire fertility biotech Gameto in a deal worth up to $1.38B. Credit: Stock.Adobe.com/Parradee

October 29th, 2026

Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion

BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.

Dave Sunderhaft, Chief Operating Officer nPhase, Inc.

October 29th, 2026

Rebuilding Clinical Data Workflows for the AI Era

As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.

October 29th, 2026

How Preventative Medications May Impact the Lingering Impact of COVID-19

Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.

October 29th, 2026

How Digital Twins Impact Recruiting During Research

Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.

Trending on PharmExec

FDA Approves Ilumya for Adults With Active Psoriatic Arthritis

Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion